Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 92.0%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 4,820,000 shares, a growth of 92.0% from the September 15th total of 2,510,000 shares. Based on an average trading volume of 518,700 shares, the short-interest ratio is currently 9.3 days. Approximately 17.2% of the company’s stock are short sold.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $9.95 on Monday. iTeos Therapeutics has a 12 month low of $8.20 and a 12 month high of $18.75. The firm has a market capitalization of $359.42 million, a PE ratio of -2.63 and a beta of 1.36. The company’s 50 day simple moving average is $13.84 and its 200 day simple moving average is $14.49.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.86. The business had revenue of $35.00 million during the quarter, compared to analyst estimates of $4.20 million. Sell-side analysts anticipate that iTeos Therapeutics will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ITOS shares. Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Monday, September 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $21.00 price target on shares of iTeos Therapeutics in a research report on Thursday, August 8th.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Creative Planning boosted its stake in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after buying an additional 1,196 shares during the period. SG Americas Securities LLC acquired a new stake in shares of iTeos Therapeutics in the 3rd quarter valued at $126,000. Clearline Capital LP acquired a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at $2,328,000. Algert Global LLC lifted its stake in shares of iTeos Therapeutics by 4.8% in the 2nd quarter. Algert Global LLC now owns 133,409 shares of the company’s stock valued at $1,980,000 after purchasing an additional 6,139 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.